NASDAQ : KALA

KALA BIO, Inc.

$0.7758 USD

-$0.07 (-8.42%)

Volume
187.52K
Average Volume
132.93K
Market Capitalization
$17.01M
P/E Ratio
-0.27
Dividend Yield
0.00%
Price Target
$18.25
Year High
$1030.00
Year Low
$0.76
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.91
Source Headline
KALA BIO Announces Reverse Stock Split

ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares.

globenewswire.com - 2026-05-07 09:00:00
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.

globenewswire.com - 2026-04-21 07:00:00

Get KALA Insider Trade Alerts

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

KALA Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$18.25

2 analysts

All Time

$12.70

5 analysts

KALA Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2025-09-30 Mizuho Downgrade Outperform Neutral
2025-09-29 HC Wainwright & Co. Downgrade Buy Neutral
2025-09-29 Ladenburg Thalmann Downgrade Buy Neutral
2025-09-29 H.C. Wainwright Downgrade Buy Neutral
2025-09-17 HC Wainwright & Co. Maintain Buy Buy
2025-09-11 Oppenheimer Maintain Outperform Outperform
2025-05-23 HC Wainwright & Co. Maintain Buy Buy
2025-04-04 HC Wainwright & Co. Maintain Buy Buy
2025-02-13 HC Wainwright & Co. Maintain Buy Buy
2024-11-15 HC Wainwright & Co. Maintain Buy Buy
2024-08-19 Oppenheimer Maintain Outperform Outperform
2024-05-17 HC Wainwright & Co. Maintain Buy Buy
2024-04-02 HC Wainwright & Co. Maintain Buy Buy
2024-04-01 Oppenheimer Maintain Outperform Outperform
2023-11-17 HC Wainwright & Co. Maintain Buy Buy
2023-08-11 HC Wainwright & Co. Maintain Buy Buy
2023-05-10 HC Wainwright & Co. Maintain Buy Buy
2023-05-01 HC Wainwright & Co. Maintain Buy Buy
2023-04-12 HC Wainwright & Co. Maintain Buy Buy
2023-03-27 HC Wainwright & Co. Maintain Buy Buy
2023-03-06 HC Wainwright & Co. Maintain Buy Buy
2022-08-15 HC Wainwright & Co. Maintain Buy Buy
2022-05-24 HC Wainwright & Co. Maintain Buy Buy
2022-05-17 HC Wainwright & Co. Maintain Buy Buy
2022-03-30 HC Wainwright & Co. Maintain Buy Buy
2022-03-30 Northland Capital Markets Maintain Outperform Outperform
2022-03-30 JP Morgan Downgrade Neutral Underweight
2021-08-06 HC Wainwright & Co. Maintain Buy Buy
2021-08-06 JP Morgan Downgrade Overweight Neutral
2021-05-06 HC Wainwright & Co. Maintain Buy Buy
2020-09-14 Jefferies Downgrade Buy Hold
2020-07-23 Northland Capital Markets Maintain Outperform Outperform
2020-06-01 Oppenheimer Maintain Outperform Outperform
2020-05-27 HC Wainwright & Co. Maintain Buy Buy
2020-05-27 JP Morgan Maintain Overweight Overweight
2020-05-08 H.C. Wainwright Maintain Buy Buy
2020-03-18 HC Wainwright & Co. Maintain Buy Buy
2020-03-10 Oppenheimer Maintain Outperform Outperform
2020-03-10 Wedbush Maintain Outperform Outperform
2019-12-17 Bank of America Downgrade Buy Neutral
2019-11-08 JP Morgan Maintain Overweight Overweight
2019-08-07 H.C. Wainwright Maintain Buy Buy
2019-04-25 Oppenheimer Maintain Outperform Outperform
2019-03-14 Jefferies Maintain Buy Buy
2018-11-14 JP Morgan Maintain Overweight Overweight
2018-08-24 H.C. Wainwright Maintain Buy Buy
2018-07-23 H.C. Wainwright Maintain Buy Buy
2018-01-25 Wells Fargo Maintain Outperform Outperform
2017-08-14 Wells Fargo Maintain Outperform Outperform
2017-08-14 Wedbush Maintain Outperform Outperform
2017-08-14 JP Morgan Maintain Overweight Overweight